Please ensure Javascript is enabled for purposes of website accessibility

Novartis Reports Q4 2019 Financial Results, Zolgensma Sales Fall Short

By Mark Prvulovic - Jan 29, 2020 at 6:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite missing some analyst targets, the pharmaceutical giant reported reasonable results overall.

Swiss pharmaceutical giant Novartis (NVS -0.20%) announced its fourth-quarter 2019 financial results this morning. The company reported net sales of $12.4 billion, which was up 8% in comparison to the same time last year. However, net income came in at just $1.13 billion, a 7% decline from Q4 2018 which was attributed primarily to a one-time, deferred tax expense.

The results were a mixed bag, with net sales beating analysts' consensus target of $12.3 billion. However, Wall Street was expecting more from the company's breakthrough gene therapy treatment, Zolgensma, which targets patients with spinal muscular atrophy. The drug, which already is the most expensive treatment in the world with a $2 million price tag, brought in $186 million in sales for the quarter. While an increase from the $160 million reported in the third quarter of 2019, it's a bit shy of the $196 million expected by analysts.

A smiling pharmacist standing in a pharmacy.

Image source: Getty Images.

Other revenue drivers for the pharmaceutical giant include the immunosuppressant Cosentyx and the blood-pressure-lowering Entresto, which is used in patients at risk of chronic heart failure. The two drugs brought in $1.7 billion and $3.6 billion in revenue respectively over the course of the year. In comparison, total Zolgensma sales came in at just $361 million for 2019.

Novartis' 2020 guidance

The company said that it expects its 2020 sales to grow somewhere in the mid-to-high single-digit percentage, with Novartis' Innovative Medicines division (which includes Cosentyx, Entresto, and Zolgensma) being the company's main revenue driver.

Novartis also highlighted the fact that it received five potential blockbuster drug approvals this year. These include Zolgensma, the breast cancer drug Piqray, a multiple sclerosis drug called Mayzent, the age-related macular degeneration drug Beovu, and Adakveo, which targets patients with sickle cell disease complications.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
NVS
$84.36 (-0.20%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.